Coronavirus disease 2019 (COVID-19) and prosthetic heart valve: An additional coagulative challenge

作     者：Attilio Allione Jacopo Davide Giamello Sara Bernardi Giulia Paglietta Giulia Lucia Massimina Cavalot Luca Alessio Dutto Daniela Caruso Andrea Tortore Giuseppe Lauria Attilio Allione;Jacopo Davide Giamello;Sara Bernardi;Giulia Paglietta;Giulia Lucia Massimina Cavalot;Luca Alessio Dutto;Daniela Caruso;Andrea Tortore;Giuseppe Lauria

作者机构：Department of Emergency MedicineSanta Croce and Carle HospitalCuneoItaly School of Emergency MedicineUniversity of TurinTurinItaly 

出 版 物：《World Journal of Emergency Medicine》 (世界急诊医学杂志（英文）)

年 卷 期：2020年第11卷第4期

页      面：258-259页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 08[工学] 080502[工学-材料学] 0805[工学-材料科学与工程（可授工学、理学学位）] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：dosage vitamin respiratory 

摘      要：Dear editor,A new infectious disease outbreak,caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),is now spreading all around the world.[1]One of the most critical understandings of the current pandemic of the coronavirus disease 2019(COVID-19)focuses on an imbalanced coagulation *** on the current evidence,we can divide the COVID-19-related hypercoagulable state into two categories[2]:patients without other pre-existing indications for anticoagulant therapy who develop a state of hypercoagulability linked to SARS-CoV-2 infection especially during the cytokine storm phase,and patients already on anticoagulation in whom we have to reevaluate their drug choices,dosages,and *** the same time,recent literature recommends the use of heparin in severe SARS-CoV-2 infection,both as thromboembolic prophylaxis and as an anticoagulant therapy,in light of possible anti-infl ammatory and antiviral mechanisms and less pharmacological interferences.[3]This indication should be adopted in all patients except for those with prosthetic heart valves,in whom vitamin K antagonists continue to remain the drug of choice.[4]In this subgroup of patients,strict monitoring of PT-INR is required to maintain the therapeutic *** purpose of this article is to underline the need for good quality evidence regarding the management of this high-risk category of the patient population.